A vs RCUS: Which Stock Is the Better Buy?
Agilent Technologies, Inc. and Arcus Biosciences, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — A vs RCUS, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Agilent Technologies, Inc. (A) | Arcus Biosciences, Inc. (RCUS) | |
|---|---|---|
| Market cap | $39.1B | $2.8B |
| Revenue (latest FY) | $6.95B | $247.00M |
| Net income (latest FY) | $1.30B | $-353.00M |
| Revenue growth (5y CAGR) | 5.4% | 25.9% |
| Net margin | 18.8% | -142.9% |
| Return on equity | 19.3% | -55.9% |
| P/E ratio | 27.8 | — |
| Dividend yield | 0.7% | — |
| Profitable years (of last 10) | 10 | 1 |
| Positive free cash flow | Yes | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full A vs RCUS breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open A's full financials → Open RCUS's full financials →Frequently asked questions
Which is bigger, A or RCUS?
Agilent Technologies, Inc. is larger by market capitalization — $39.1B versus $2.8B.
Which grows faster, A or RCUS?
Over the last five fiscal years, Arcus Biosciences, Inc. grew revenue faster — 25.9%/yr versus 5.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.